The initial finding that TRAIL can induce toxicity of cancer cells by induction of apoptosis without causing toxicity in mice has strongly stimulated the development of drug candidates, mainly agonistic anti-TRAIL-R1 and anti-TRAIL-R2 that activate TRAIL apoptotic signaling [278]. This evidence concerns the gene TNFSF10 and cancer.